Lineage Cell Therapeutics Inc. — Director's Dealing 2021

Jun 21, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lineage Cell Therapeutics, Inc. (LCTX)
CIK: 0000876343
Period of Report: 2021-06-18

Reporting Person: Mulroy Michael H. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-18	Common Shares, no par value	M	24720	$2.20	Acquired	251555	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-18	Stock Option (right to buy)	$2.20	M	24720	Disposed	2021-06-30	Common Shares (24720)	Direct

Footnotes

F1: This option became exercisable in four equal quarterly installments after the date of grant on July 1, 2016.